ACH 24

Drug Profile

ACH 24

Alternative Names: ACH24

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Ache Laboratories
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Vitiligo

Most Recent Events

  • 15 Mar 2016 Brazilian Health Surveillance Agency (ANVISA) requests Ache Laboratories to conduct a phase I trial of ACH 24
  • 15 Mar 2016 Ache Laboratories withdraws a phase III trial for Vitiligo in Brazil (NCT01419964)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top